Fig 1: I-BET protects against cytokine-induced apoptosis by antagonizing NF-kB signaling. Under inflammation, cytokines bind to their receptors, leading to the phosphorylation of IKKA/B, which in turn leads to the phosphorylation and degradation of IκBα, relieving p65 inhibition. Phospho-p65 then translocates to the nucleus, interacting with BRD proteins and regulating NF-κB target gene transcription, including the repression of β-cell function-related genes such as INS-1, Ins2, and Pdx1, and anti-apoptotic genes (Xiap), and the activation of inflammatory genes such as Myc, leading to reduced insulin secretion, β-cell dysfunction, and ultimately apoptosis. However, when treated with I-BET, the phosphorylation of IKKA/B, IκBα, and p65 is reduced, inhibiting the binding of BRD to p65, indicating an overall decrease in NF-κB pathway activity, reversing the gene expression alterations, improving β-cell function, and reducing apoptosis. Additionally, I-BET-regulated Foxo1 expression and its downstream target Sod1 reduce oxidative stress.
Fig 2: Characterization of pancreatic progenitors (PP)(A) Brightfield images of a hiPSC culture at high (left) and low (right) confluency, one day after splitting.(B) Brightfield images of a healthy hiPSC culture with defined edges (left) and a differentiated unhealthy hiPSC culture with stromal-like morphologies and heterogenous cells (right).(C) Immunofluorescence of hiPSC at the beginning of the differentiation, validated for expression of the pluripotency markers OCT4, NANOG, and SOX2.(D) Immunofluorescence for DE markers SOX17 and pluripotent marker OCT4 at the DE stage, HNF1B at the PF stage, and PDX1, NKX6.1, and SOX9 at the PP stage.(E) Example of a suboptimal differentiation characterized by few and low expressing PDX1, NKX6.1 and SOX9 positive cells at the PP stage. Scale bars, 50 μm (A, B, D and E) and 30 μm (C).Adapted from Cujba et al. (2022).
Fig 3: Effect of FOXA2 loss on pancreatic progenitor (PP) differentiation. A Schematic representation of iPSC differentiation protocol into pancreatic progenitors (PPs). B Western blot analysis confirming the absence of FOXA2 expression in PPs derived from FOXA2–/– iPSCs. Immunofluorescence (C) and RT-qPCR (D) showing significant reduction in the expression of PDX1 and NKX6.1 in FOXA2–/– PPs. Scale bars = 100 μm. Data are represented as mean ± SD; ***p < 0.001 (n = 4)
Fig 4: Characterization of the differentiated H1 ES cells at the Pancreatic Progenitor (PP) and the Endocrine Progenitor (EN) stages.(A) From left to right, flow cytometry for PDX1/FOXA2, immunofluorescence staining for PDX1, and qRT-PCR analysis for the PP-specific genes in the differentiated cells at stage 3. (B) Flow cytometry for NGN3/NKX6.1, immunofluorescence staining for NGN3, qRT-PCR analysis for the EP-specific genes and below, immunofluorescence staining for PDX1/NKX6.1 in the differentiated cells at stage 4. (C) Immunofluorescence staining for ARX/PAX4, and qRT-PCR analysis for ARX and PAX4 in differentiated cells at the stage 4. Scale bar = 40μm. (*p< 0.05, **p< 0.01, p***<0.001, unpaired two-tailed t-test, n = 3).
Fig 5: Characterization of endocrine markers in hPSC-derived MPCs. Immunofluorescence images of hPSC-derived MPCs using protocol 2 showing the expression of chromogranin A (CHGA; green) and NKX6.1 (red) in monolayer culture (a, b) and 3D aggregates (c). High magnification images showed that CHGA and NKX6.1 (arrowheads) were not colocalized in the same cells (b). The 3D aggregates showed no expression of CHGA, an early endocrine marker (c). d Immunofluorescence images of hPSC-derived MPCs showing expression of CHGA (green) and NKX2.2 (red). NKX2.2 was noticed in the 3D aggregates in the absence of CHGA, but both were expressed in the area surrounding the 3D aggregates. e Immunofluorescence images of hPSC-derived MPCs showing expression of neurogenin 3 (NGN3; green) and NKX6.1 (red). Note the absence of NGN3 in NKX6.1+ cells (arrowheads). f Immunofluorescence images of hPSC-derived MPCs showing expression of CHGA (red) and PDX1 (green). Note the presence of CHGA in the same areas expressing PDX1. All data shown are representative results from at least three independent experiments. Scale bars (a, c) = 100 μm and (b, d, e, f) = 50 μm
Supplier Page from Abcam for Anti-PDX1 antibody